| Literature DB >> 21527995 |
Jeffrey J Dunmire1, Rachida Bouhenni, Michael L Hart, Bassam T Wakim, Anthony M Chomyk, Sarah E Scott, Hiroshi Nakamura, Deepak P Edward.
Abstract
PURPOSE: To identify candidate protein biomarkers in sera indicative of acute retinal injury.Entities:
Mesh:
Substances:
Year: 2011 PMID: 21527995 PMCID: PMC3081796
Source DB: PubMed Journal: Mol Vis ISSN: 1090-0535 Impact factor: 2.367
Figure 1Fundus examination and histological evaluation of severe and MVL type laser lesions in a retina. A: Rows of severe lesions (arrows) and MVL (arrow heads) caught by fundus imaging immediately following laser treatment. B-D: Histology of normal and laser-treated retina 1 day following laser injury. B: Normal retina adjacent to the region that was treated with laser. Note the intact sensory retina and retinal pigment epithelium. C: Minimally visible lesions show mild swelling of the outer nuclear layer (line), condensation of cone inner segments (arrow), and mild disruption of photoreceptor outer segments (*) and RPE. The inner retina and underlying choroid are unaffected. D: A severe retinal lesion showing outer retinal swelling with disruption of the outer nuclear layer, the outer plexiform layer, and portions of the inner nuclear layer (line). Note the mummification of photoreceptor inner segments (*), as indicated by shrinkage and condensation (arrow). Also note mummification [69,70] of the underlying photoreceptor outer segments and RPE (hematoxylin and eosin, original magnification 20×).
Proteins with significantly higher spectral counts in serum following laser treatment compared with control.
| Time post-treatment | Human homolog gene ID | Protein description | Number samples w/ positive detection | Normalized scan count ratio (treated/control) | Holm-Sidak adjusted p-value | ||
|---|---|---|---|---|---|---|---|
| Control (n=6) | Treated (n=6) | ||||||
| 4h | Q8SPT9 | 3875 | Keratin 18 (CK18) | 1 | 6 | 16.8935 | 0.000783 |
| 4h | Q3YAQ9 | 5230 | Phosphoglycerate kinase 1 (PGK1) | 5 | 6 | 5.0837 | 0.000309 |
| 4h | Q6XML5 | 721 | Complement factor 4 (C4) | 6 | 6 | 2.7795 | 0.019637 |
| 4h | Q8WNP0 | 2525 | Lewis alpha-3-fucosyltransferase (FUT3) | 6 | 6 | 2.2793 | 0.002356 |
| 4h | Q1HKZ4 | 1969 | Ephrin receptor A2 (EPHA2) | 6 | 6 | 2.2169 | 0.003633 |
| 4h | Q9TUC6 | 1138 | Nicotinic receptor alpha 5 subunit (CHRNA5) | 0 | 5 | - | 0.003949 |
| 4h | Q28864 | 7035 | Tissue factor pathway inhibitor (TFPI) | 0 | 4 | - | 0.029670 |
| 4h | B0JDR3 | 3106 | MHC class I antigen (HLA-B) | 0 | 3 | - | 0.001778 |
| 1 Day | Q3YAQ9 | 5230 | Phosphoglycerate kinase 1 (PGK1) | 2 | 6 | 24.6994 | 2.62E-13 |
| 1 Day | Q8SPT9 | 3875 | Keratin 18 (CK18) | 2 | 6 | 22.7121 | 5.42E-12 |
| 1 Day | Q8WNP0 | 2525 | Lewis alpha-3-fucosyltransferase (FUT3) | 5 | 6 | 15.3307 | 0.00E+00 |
| 1 Day | B1NL87 | 64816 | Cytochrome P450, 3A43 (CYP3A43) | 3 | 6 | 6.2458 | 0.013228 |
| 1 Day | A9XEK3 | 146 | Alpha-1D adrenoceptor (ADRA1D) | 4 | 5 | 6.0684 | 0.00E+00 |
| 1 Day | P47899 | 153 | Beta-1 adrenergic receptor (ADRB1) | 3 | 4 | 4.3532 | 0.000097 |
| 1 Day | Q5TM61 | 5514 | Protein phosphatase 1, regulatory subunit 10 (PPP1R10) | 5 | 6 | 4.3240 | 4.47E-07 |
| 1 Day | B3Y660 | 51311 | Toll-like receptor 8 (TLR8) | 6 | 6 | 3.2290 | 0.00E+00 |
| 1 Day | Q1HKZ4 | 1969 | Ephrin receptor A2 (EPHA2) | 6 | 6 | 2.7874 | 0.000157 |
| 1 Day | Q8HYQ1 | 6352 | C-C motif chemokine 5 (CCL5) | 0 | 6 | - | 0.000238 |
| 1 Day | Q3YAN2 | 51185 | Cereblon (CRBN) | 0 | 6 | - | 0.016533 |
| 1 Day | Q4G3V3 | 793 | 28kDa calbindin 1 (CALB1) | 0 | 6 | - | 0.041927 |
| 3 Days | Q50KV9 | 54429 | Taste receptor type 2 (TAS2R5) | 3 | 5 | 5.6981 | 0.002844 |
| 3 Days | B0S4P2 | 148 | Alpha-1A adrenoceptor (ADRA1A) | 4 | 6 | 5.2097 | 0.011880 |
| 3 Days | Q9N143 | 7297 | Tyrosine kinase-2 (TYK2) | 6 | 6 | 2.2057 | 0.021489 |
Figure 2Proteins with significantly higher spectral counts at two time points following laser treatment. Counts are represented as mean number of normalized scans±SEM for control (n=6) and treated samples (n=6) at 4 h (4 h), 1 day (1 day), and 3 days (3 days) following either mock or laser treatment. *p≤0.05, **p≤0.01, ***p≤0.001, for significant differences in treated samples compared with corresponding controls at each time point.
Gene ontology. Proteins with significantly higher spectral counts in serum following laser treatment compared with mock control, organized by gene ontology (GO) terms for cellular localization and biologic process.
| Protein description | Biological process GO term | Cellular component GO term |
|---|---|---|
| Alpha-1D adrenoceptor (ADRA1D) | GO:0007165-Signal transduction | GO:0016021-Integral to membrane |
| Beta-1 adrenergic receptor (ADRB1) | GO:0007165-Signal transduction | GO:0016021-Integral to membrane |
| Ephrin receptor A2 (EPHA2) | GO:0007165-Signal transduction | GO:0016021-Integral to membrane |
| Taste receptor type 2 (TAS2R5) | GO:0007165-Signal transduction | GO:0016021-Integral to membrane |
| Nicotinic receptor alpha 5 subunit (CHRNA5) | GO:0007165-Signal transduction | GO:0016021-Integral to membrane |
| Alpha-1A adrenoceptor (ADRA1A) | GO:0007165-Signal transduction | GO:0016021-Integral to membrane |
| Toll-like receptor 8 (TLR8) | GO:0006955-Immune response | GO:0016021-Integral to membrane |
| MHC class I antigen (HLA-B) | GO:0006955-Immune response | GO:0016021-Integral to membrane |
| Lewis alpha-3-fucosyltransferase (FUT3) | GO:0043687-Post-translational protein modification | GO:0031090-Organelle membrane |
| Cytochrome P450, 3A43 (CYP3A43) | GO:0055114-Oxidation reduction | GO:0031090-Organelle membrane |
| Phosphoglycerate kinase 1 (PGK1) | GO:0043687-Post-translational protein modification | GO:0005737-Cytoplasm |
| Cereblon (CRBN) | GO:0043687-Post-translational protein modification | GO:0005737-Cytoplasm |
| Tyrosine kinase-2 (TYK2) | GO:0043687-Post-translational protein modification | GO:0005737-Cytoplasm |
| Keratin 18 (CK18) | GO:0006915-Apoptosis | GO:0005737-Cytoplasm |
| 28kDa calbindin 1 (CALB1) | GO:0048167-Regulation of synaptic plasticity | GO:0005737-Cytoplasm |
| Protein phosphatase 1, regulatory subunit 10 (PPP1R10) | GO:0006350-Transcription | GO:0005634-Nucleus |
| C-C motif chemokine 5 (CCL5) | GO:0006954-Inflammatory response | GO:0005576-Extracellular region |
| Complement factor 4 (C4) | GO:0006954-Inflammatory response | GO:0005576-Extracellular region |
| Tissue factor pathway inhibitor (TFPI) | GO:0007596-Blood coagulation | GO:0005576-Extracellular region |